ARGNF News and Press, Argen X SE

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART&...

2026-02-27 06:50:00 ET The following segment was excerpted from the Baron International Growth Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Baron International Growth Fund Q4 2025: Contribut...

2026-02-26 12:57:59 ET argenx SE (ARGX) Q4 2025 Earnings Call February 26, 2026 8:30 AM EST Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Karen Massey - Chief Operating Officer Luc Truyen - Chief Medic...

2026-02-26 07:30:00 ET The following segment was excerpted from the Artisan Global Discovery Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Artisan Global Discovery Fund Q4 2025 Winners, Lagga...

2026-02-26 01:19:02 ET More on argenx SE argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Argenx: TED Phase 3 Failure, Vyvgart Growth, And Why ...

$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year ‑ over ‑ year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by...

Study met primary endpoint (p-value = 0.012) First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to ex...

2026-02-23 19:20:00 ET The following segment was excerpted from the Allspring Premier Large Company Growth Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Allspring Premier Large Company Growth...

February 23, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Operating Officer, will participate in a fires...

February 19, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, Febr...